Track Novartis AG — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Novartis AG 0QLR.IL Open Novartis AG in new tab

117.61 CHF
P/E
36.56
EPS
3.21
Yield
3.78%
P/B
4.68
ROE
13.32
Beta
0.49
Loading chart...
Key Metrics
P/E36.56
EPS3.21
Book Value25.07
Price to Book4.68
Debt/Equity54.57
% Insiders3.947%
Growth
Revenue Growth0.07%
Earnings Growth0.44%
Dividend
Dividend Yield3.78%
Annual dividends3.20 CHF
Ex-Div. DateMarch 10, 2026
Payout97.31%

DCF Valuation

Tweak assumptions to recompute fair value for Novartis AG (0QLR.IL)
Currency: CHF
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Novartis AG Logo Novartis AG Analysis (0QLR.IL)

Switzerland Health Care Official Website Stock

Is Novartis AG a good investment? Novartis AG (0QLR.IL) is currently trading at 117.61 CHF.

In terms of valuation, the stock trades at a P/E ratio of 36.56. This high multiple suggests investors have priced in significant future growth expectations.

For income investors, Novartis AG pays a dividend yield of 3.78%. With a payout ratio of 97%, the dividend appears to be under pressure.

Investor FAQ

Does Novartis AG pay a dividend?

Yes, it pays an annual dividend of 3.20 CHF (3.78% yield).

What asset class is Novartis AG?

Novartis AG is classified as a Stock. You can compare it against 10 other assets in the "Related Symbols" list on this page.

Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Exchange Ticker
BUE (Argentina) NVS.BA
BUE (Argentina) NVSD.BA
IOB (United Kingdom) 0QLR.IL
FRA (Germany) NOTA.F
STU (Germany) NOTA.SG
SAO (Brazil) N1VS34.SA
MEX (Mexico) NVSN.MX
PNK (United States) NVSEF
EBS (Ireland) NOVN.SW
NYQ (United States) NVS
Dividend Yield

3.78%

Annual Dividends

3.20 CHF

Next ex. div date

March 10, 2026

Payout Ratio

97.31%

Historical Dividends
Year Total Dividends
2027 3.81 CHF
2026 3.70 CHF
2025 3.50 CHF
2024 3.30 CHF
2023 3.20 CHF
2022 3.10 CHF
2021 3.00 CHF
2020 2.95 CHF
2018 2.80 CHF
2017 2.75 CHF

Yearly aggregated dividends

Dividends

Novartis AG
Mar 10, 2026 Paid
Dividend
3.7 CHF

Historical Split Corporate Actions

Split Date Split Ratio to 1
Oct. 4, 2023 1.200000
Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion